1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 12, 1996
DURAMED PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-15242 11-2590026
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
7155 East Kemper Road, Cincinnati, Ohio 45249 (513) 731-9900
(Address and telephone number, including area code, of principal
executive offices)
2
INFORMATION TO BE INCLUDED IN THE REPORT
Items 1, 3, 4, 5, 6 and 8 are not applicable and are omitted from this Report.
Item 2. Acquisition or Disposition of Assets
The information called for by this Item is contained in the Company's
press release dated September 13, 1996 relating to the acquisition of
Hallmark Pharmaceuticals, Inc., attached hereto as Exhibit 99.1 and
incorporated herein by reference, and in the Proxy Statement/Prospectus
dated August 8, 1996 (contained in the Company's Registration Statement
(No. 333-6901) on Form S-4, as amended), attached hereto as Exhibit
99.2 and incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial
Information and Exhibits.
(a) Financial Statements of Business Acquired.
The information called for by this Item is contained in
Exhibit 99.2, attached hereto and incorporated herein by
reference.
(b) Pro Forma Financial Information.
The information called for by this Item is contained in
Exhibit 99.2, attached hereto and incorporated herein by
reference.
(c) Exhibits.
The following exhibits are filed with this Report on Form 8-K:
Regulation S-K
Exhibit No. Exhibit
2 Asset Purchase Agreement (previously
filed as a portion of Exhibit 99 to
the Company's Current Report on Form
8-K dated August 8, 1996 and
incorporated herein by reference)
99.1 Press Release dated September 13,
1996.
99.2 Proxy Statement/Prospectus dated
August 8, 1996
-2-
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 26, 1996 DURAMED PHARMACEUTICALS, INC.
By /s/ Timothy J. Holt
---------------------------------
Timothy J. Holt
Senior Vice President-Finance and
Administration
-3-